Loading…

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma

Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients....

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2019-10, Vol.110 (10), p.3267-3274
Main Authors: Maekawa, Keiko, Ri, Masaki, Nakajima, Miki, Sekine, Akihiro, Ueda, Ryuzo, Tohkin, Masahiro, Miyata, Naoki, Saito, Yoshiro, Iida, Shinsuke
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293
cites cdi_FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293
container_end_page 3274
container_issue 10
container_start_page 3267
container_title Cancer science
container_volume 110
creator Maekawa, Keiko
Ri, Masaki
Nakajima, Miki
Sekine, Akihiro
Ueda, Ryuzo
Tohkin, Masahiro
Miyata, Naoki
Saito, Yoshiro
Iida, Shinsuke
description Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN. Fifty‐nine serum samples were collected from patients with MM prior to receiving BTZ plus low‐dose dexamethasone therapy. Serum levels of phospholipids, sphingolipids, neutral lipids, and polyunsaturated fatty acids and their oxidation products were measured by a comprehensive lipidomic study. Overall, 385 lipid metabolites were identified in patients’ sera; lower levels of several glycerophospholipids, sphingolipids, and cholesteryl esters were associated with a poor treatment response. Metabolites related to platelet‐activating factor biosynthesis and cholesterol metabolism appeared particularly relevant. Furthermore, several lysophosphatidylcholines, phosphatidylcholines, ceramides, neutral lipids, and oxidative fatty acids were significantly increased or decreased in patients with BiPN grades ranging from G0 to G3. Among these compounds, mediators reportedly inducing myelin breakdown and stimulating inflammatory responses were prominent. Although further study is necessary to validate these biomarker candidates, our results contribute to the development of predictive biomarkers for response to BTZ treatment, or ensuing severe BiPN, in patients with MM. This study aimed to explore lipid biomarker candidates to predict the response to bortezomib (BTZ) and the severity of BTZ‐induced peripheral neuropathy (BiPN) in multiple myeloma (MM) patients. A comprehensive lipidomic analysis was carried out using pretreatment sera from MM patients who received BTZ plus low‐dose dexamethasone therapy. The response‐associated metabolites appear to be involved in platelet‐activating factor biosynthesis and cholesterol metabolism, whereas the BiPN‐associated metabolites seem to be implicated in the myelin breakdown and inflammatory responses.
doi_str_mv 10.1111/cas.14178
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6778623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2467260236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293</originalsourceid><addsrcrecordid>eNp9kUtLxDAYRYMovhf-AQm4clHNu8lGkMEXCC7UdUg6qRNtm5q06vjrjY6KLjSbBL6Tw_24AOxgdIDzOaxMOsAMl3IJrGPKVFEiJJY_3mWhECVrYCOle4SoYIqtgjWKGWOSinVgrl0cW9j43k9D66sE6xChe-mbEH13B60PrYkPLiYYamhDHNxr5iwcZi6afg59B3szeNcNCT77YQbbsRl83zjYzl2TP2-Bldo0yW1_3pvg9vTkZnJeXF6dXUyOL4uKKS4LJxVnquRTLPIijBFuuMXCVKom1laUC2YQt6K0RKpqSg13XCpppSBCYqLoJjhaePvRtm5a5UTRNLqPPi8w18F4_XvS-Zm-C09alGWW0CzY-xTE8Di6NOj7MMYuZ9aEiZIIRKj4l6III46QkpnaX1BVDClFV3_nwEi_d6ZzZ_qjs8zu_gz-TX6VlIHDBfDsGzf_26Qnx9cL5RvEhaFE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2301050098</pqid></control><display><type>article</type><title>Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>PubMed Central database</source><source>ProQuest Publicly Available Content database</source><creator>Maekawa, Keiko ; Ri, Masaki ; Nakajima, Miki ; Sekine, Akihiro ; Ueda, Ryuzo ; Tohkin, Masahiro ; Miyata, Naoki ; Saito, Yoshiro ; Iida, Shinsuke</creator><creatorcontrib>Maekawa, Keiko ; Ri, Masaki ; Nakajima, Miki ; Sekine, Akihiro ; Ueda, Ryuzo ; Tohkin, Masahiro ; Miyata, Naoki ; Saito, Yoshiro ; Iida, Shinsuke</creatorcontrib><description>Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN. Fifty‐nine serum samples were collected from patients with MM prior to receiving BTZ plus low‐dose dexamethasone therapy. Serum levels of phospholipids, sphingolipids, neutral lipids, and polyunsaturated fatty acids and their oxidation products were measured by a comprehensive lipidomic study. Overall, 385 lipid metabolites were identified in patients’ sera; lower levels of several glycerophospholipids, sphingolipids, and cholesteryl esters were associated with a poor treatment response. Metabolites related to platelet‐activating factor biosynthesis and cholesterol metabolism appeared particularly relevant. Furthermore, several lysophosphatidylcholines, phosphatidylcholines, ceramides, neutral lipids, and oxidative fatty acids were significantly increased or decreased in patients with BiPN grades ranging from G0 to G3. Among these compounds, mediators reportedly inducing myelin breakdown and stimulating inflammatory responses were prominent. Although further study is necessary to validate these biomarker candidates, our results contribute to the development of predictive biomarkers for response to BTZ treatment, or ensuing severe BiPN, in patients with MM. This study aimed to explore lipid biomarker candidates to predict the response to bortezomib (BTZ) and the severity of BTZ‐induced peripheral neuropathy (BiPN) in multiple myeloma (MM) patients. A comprehensive lipidomic analysis was carried out using pretreatment sera from MM patients who received BTZ plus low‐dose dexamethasone therapy. The response‐associated metabolites appear to be involved in platelet‐activating factor biosynthesis and cholesterol metabolism, whereas the BiPN‐associated metabolites seem to be implicated in the myelin breakdown and inflammatory responses.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.14178</identifier><identifier>PMID: 31444836</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor - blood ; Bortezomib ; Bortezomib - administration &amp; dosage ; Bortezomib - adverse effects ; Cholesterol ; Cholesterol Esters - blood ; Chromatography ; Dexamethasone ; Esters ; Fatty acids ; Female ; Fourier transforms ; Glycerophospholipids - blood ; Humans ; Inflammation ; Kidney cancer ; Lipid metabolism ; lipidomics ; Lipids ; Lipids - blood ; Male ; Mass spectrometry ; Metabolism ; Metabolites ; Metabolomics - methods ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - blood ; Multiple Myeloma - chemistry ; Multiple Myeloma - drug therapy ; Myelin ; Original ; Oxidation ; Pain ; Patients ; Peripheral Nervous System Diseases - chemically induced ; Peripheral neuropathy ; Pharmaceuticals ; Phospholipids ; Polyunsaturated fatty acids ; Proteasome inhibitors ; R&amp;D ; Research &amp; development ; Research funding ; response rate ; Scientific imaging ; Serum levels ; Severity of Illness Index ; Software ; Sphingolipids ; Sphingolipids - blood ; Treatment Outcome</subject><ispartof>Cancer science, 2019-10, Vol.110 (10), p.3267-3274</ispartof><rights>2019 The Authors. published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2019 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293</citedby><cites>FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293</cites><orcidid>0000-0002-4951-960X ; 0000-0003-4857-4137 ; 0000-0002-9617-486X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2301050098/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2301050098?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31444836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maekawa, Keiko</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Nakajima, Miki</creatorcontrib><creatorcontrib>Sekine, Akihiro</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Tohkin, Masahiro</creatorcontrib><creatorcontrib>Miyata, Naoki</creatorcontrib><creatorcontrib>Saito, Yoshiro</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><title>Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN. Fifty‐nine serum samples were collected from patients with MM prior to receiving BTZ plus low‐dose dexamethasone therapy. Serum levels of phospholipids, sphingolipids, neutral lipids, and polyunsaturated fatty acids and their oxidation products were measured by a comprehensive lipidomic study. Overall, 385 lipid metabolites were identified in patients’ sera; lower levels of several glycerophospholipids, sphingolipids, and cholesteryl esters were associated with a poor treatment response. Metabolites related to platelet‐activating factor biosynthesis and cholesterol metabolism appeared particularly relevant. Furthermore, several lysophosphatidylcholines, phosphatidylcholines, ceramides, neutral lipids, and oxidative fatty acids were significantly increased or decreased in patients with BiPN grades ranging from G0 to G3. Among these compounds, mediators reportedly inducing myelin breakdown and stimulating inflammatory responses were prominent. Although further study is necessary to validate these biomarker candidates, our results contribute to the development of predictive biomarkers for response to BTZ treatment, or ensuing severe BiPN, in patients with MM. This study aimed to explore lipid biomarker candidates to predict the response to bortezomib (BTZ) and the severity of BTZ‐induced peripheral neuropathy (BiPN) in multiple myeloma (MM) patients. A comprehensive lipidomic analysis was carried out using pretreatment sera from MM patients who received BTZ plus low‐dose dexamethasone therapy. The response‐associated metabolites appear to be involved in platelet‐activating factor biosynthesis and cholesterol metabolism, whereas the BiPN‐associated metabolites seem to be implicated in the myelin breakdown and inflammatory responses.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Bortezomib</subject><subject>Bortezomib - administration &amp; dosage</subject><subject>Bortezomib - adverse effects</subject><subject>Cholesterol</subject><subject>Cholesterol Esters - blood</subject><subject>Chromatography</subject><subject>Dexamethasone</subject><subject>Esters</subject><subject>Fatty acids</subject><subject>Female</subject><subject>Fourier transforms</subject><subject>Glycerophospholipids - blood</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Kidney cancer</subject><subject>Lipid metabolism</subject><subject>lipidomics</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metabolomics - methods</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - chemistry</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Myelin</subject><subject>Original</subject><subject>Oxidation</subject><subject>Pain</subject><subject>Patients</subject><subject>Peripheral Nervous System Diseases - chemically induced</subject><subject>Peripheral neuropathy</subject><subject>Pharmaceuticals</subject><subject>Phospholipids</subject><subject>Polyunsaturated fatty acids</subject><subject>Proteasome inhibitors</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Research funding</subject><subject>response rate</subject><subject>Scientific imaging</subject><subject>Serum levels</subject><subject>Severity of Illness Index</subject><subject>Software</subject><subject>Sphingolipids</subject><subject>Sphingolipids - blood</subject><subject>Treatment Outcome</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kUtLxDAYRYMovhf-AQm4clHNu8lGkMEXCC7UdUg6qRNtm5q06vjrjY6KLjSbBL6Tw_24AOxgdIDzOaxMOsAMl3IJrGPKVFEiJJY_3mWhECVrYCOle4SoYIqtgjWKGWOSinVgrl0cW9j43k9D66sE6xChe-mbEH13B60PrYkPLiYYamhDHNxr5iwcZi6afg59B3szeNcNCT77YQbbsRl83zjYzl2TP2-Bldo0yW1_3pvg9vTkZnJeXF6dXUyOL4uKKS4LJxVnquRTLPIijBFuuMXCVKom1laUC2YQt6K0RKpqSg13XCpppSBCYqLoJjhaePvRtm5a5UTRNLqPPi8w18F4_XvS-Zm-C09alGWW0CzY-xTE8Di6NOj7MMYuZ9aEiZIIRKj4l6III46QkpnaX1BVDClFV3_nwEi_d6ZzZ_qjs8zu_gz-TX6VlIHDBfDsGzf_26Qnx9cL5RvEhaFE</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Maekawa, Keiko</creator><creator>Ri, Masaki</creator><creator>Nakajima, Miki</creator><creator>Sekine, Akihiro</creator><creator>Ueda, Ryuzo</creator><creator>Tohkin, Masahiro</creator><creator>Miyata, Naoki</creator><creator>Saito, Yoshiro</creator><creator>Iida, Shinsuke</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid><orcidid>https://orcid.org/0000-0003-4857-4137</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid></search><sort><creationdate>201910</creationdate><title>Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma</title><author>Maekawa, Keiko ; Ri, Masaki ; Nakajima, Miki ; Sekine, Akihiro ; Ueda, Ryuzo ; Tohkin, Masahiro ; Miyata, Naoki ; Saito, Yoshiro ; Iida, Shinsuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Bortezomib</topic><topic>Bortezomib - administration &amp; dosage</topic><topic>Bortezomib - adverse effects</topic><topic>Cholesterol</topic><topic>Cholesterol Esters - blood</topic><topic>Chromatography</topic><topic>Dexamethasone</topic><topic>Esters</topic><topic>Fatty acids</topic><topic>Female</topic><topic>Fourier transforms</topic><topic>Glycerophospholipids - blood</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Kidney cancer</topic><topic>Lipid metabolism</topic><topic>lipidomics</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metabolomics - methods</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - chemistry</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Myelin</topic><topic>Original</topic><topic>Oxidation</topic><topic>Pain</topic><topic>Patients</topic><topic>Peripheral Nervous System Diseases - chemically induced</topic><topic>Peripheral neuropathy</topic><topic>Pharmaceuticals</topic><topic>Phospholipids</topic><topic>Polyunsaturated fatty acids</topic><topic>Proteasome inhibitors</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Research funding</topic><topic>response rate</topic><topic>Scientific imaging</topic><topic>Serum levels</topic><topic>Severity of Illness Index</topic><topic>Software</topic><topic>Sphingolipids</topic><topic>Sphingolipids - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maekawa, Keiko</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Nakajima, Miki</creatorcontrib><creatorcontrib>Sekine, Akihiro</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Tohkin, Masahiro</creatorcontrib><creatorcontrib>Miyata, Naoki</creatorcontrib><creatorcontrib>Saito, Yoshiro</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley-Blackwell Open Access Backfiles</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maekawa, Keiko</au><au>Ri, Masaki</au><au>Nakajima, Miki</au><au>Sekine, Akihiro</au><au>Ueda, Ryuzo</au><au>Tohkin, Masahiro</au><au>Miyata, Naoki</au><au>Saito, Yoshiro</au><au>Iida, Shinsuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2019-10</date><risdate>2019</risdate><volume>110</volume><issue>10</issue><spage>3267</spage><epage>3274</epage><pages>3267-3274</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients. This study aimed to explore serum lipid biomarker candidates to predict the response to BTZ and the severity of BiPN. Fifty‐nine serum samples were collected from patients with MM prior to receiving BTZ plus low‐dose dexamethasone therapy. Serum levels of phospholipids, sphingolipids, neutral lipids, and polyunsaturated fatty acids and their oxidation products were measured by a comprehensive lipidomic study. Overall, 385 lipid metabolites were identified in patients’ sera; lower levels of several glycerophospholipids, sphingolipids, and cholesteryl esters were associated with a poor treatment response. Metabolites related to platelet‐activating factor biosynthesis and cholesterol metabolism appeared particularly relevant. Furthermore, several lysophosphatidylcholines, phosphatidylcholines, ceramides, neutral lipids, and oxidative fatty acids were significantly increased or decreased in patients with BiPN grades ranging from G0 to G3. Among these compounds, mediators reportedly inducing myelin breakdown and stimulating inflammatory responses were prominent. Although further study is necessary to validate these biomarker candidates, our results contribute to the development of predictive biomarkers for response to BTZ treatment, or ensuing severe BiPN, in patients with MM. This study aimed to explore lipid biomarker candidates to predict the response to bortezomib (BTZ) and the severity of BTZ‐induced peripheral neuropathy (BiPN) in multiple myeloma (MM) patients. A comprehensive lipidomic analysis was carried out using pretreatment sera from MM patients who received BTZ plus low‐dose dexamethasone therapy. The response‐associated metabolites appear to be involved in platelet‐activating factor biosynthesis and cholesterol metabolism, whereas the BiPN‐associated metabolites seem to be implicated in the myelin breakdown and inflammatory responses.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>31444836</pmid><doi>10.1111/cas.14178</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid><orcidid>https://orcid.org/0000-0003-4857-4137</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1347-9032
ispartof Cancer science, 2019-10, Vol.110 (10), p.3267-3274
issn 1347-9032
1349-7006
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6778623
source Open Access: Wiley-Blackwell Open Access Journals; PubMed Central database; ProQuest Publicly Available Content database
subjects Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - blood
Bortezomib
Bortezomib - administration & dosage
Bortezomib - adverse effects
Cholesterol
Cholesterol Esters - blood
Chromatography
Dexamethasone
Esters
Fatty acids
Female
Fourier transforms
Glycerophospholipids - blood
Humans
Inflammation
Kidney cancer
Lipid metabolism
lipidomics
Lipids
Lipids - blood
Male
Mass spectrometry
Metabolism
Metabolites
Metabolomics - methods
Middle Aged
Multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - chemistry
Multiple Myeloma - drug therapy
Myelin
Original
Oxidation
Pain
Patients
Peripheral Nervous System Diseases - chemically induced
Peripheral neuropathy
Pharmaceuticals
Phospholipids
Polyunsaturated fatty acids
Proteasome inhibitors
R&D
Research & development
Research funding
response rate
Scientific imaging
Serum levels
Severity of Illness Index
Software
Sphingolipids
Sphingolipids - blood
Treatment Outcome
title Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A20%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20lipidomics%20for%20exploring%20biomarkers%20of%20bortezomib%20therapy%20in%20patients%20with%20multiple%20myeloma&rft.jtitle=Cancer%20science&rft.au=Maekawa,%20Keiko&rft.date=2019-10&rft.volume=110&rft.issue=10&rft.spage=3267&rft.epage=3274&rft.pages=3267-3274&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.14178&rft_dat=%3Cproquest_pubme%3E2467260236%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4958-e8954975d161784425a5b16ac9f2bbc3564a05b67b289cd3a5e5898b862681293%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2301050098&rft_id=info:pmid/31444836&rfr_iscdi=true